RESUMO
Defensins are highly abundant antimicrobial peptides in the female genital mucosa. We have previously shown that human defensins 5 and 6 (HD5 and HD6), produced by cervicovaginal epithelial cells, significantly enhance HIV infectivity in vitro. Candidate polyanion microbicides, including PRO 2000, cellulose sulfate and carrageenan, failed to protect women against HIV infection in large-scale clinical trials, but the molecular basis of ineffectiveness was not clear. We hypothesized that mucosal host factors such as HD5 an HD6 may alter the activity of polyanion microbicides against HIV. Our results demonstrated that HD5 and HD6 but not their linear analogs antagonized the anti-HIV activity of PRO 2000, cellulose sulfate and carrageenan in vitro. Polyanion microbicides also reduced the HIV-enhancing effect of these defensins. We conclude that mucosal host factors could negatively impact the efficacy of topical microbicides against HIV, and their impact on the activity of candidate microbicides needs to be considered during the preclinical evaluation.
Assuntos
Fármacos Anti-HIV/antagonistas & inibidores , Anti-Infecciosos/antagonistas & inibidores , Defensinas/metabolismo , HIV-1/efeitos dos fármacos , HIV-1/patogenicidade , Mucosa/imunologia , Polímeros/farmacologia , Fármacos Anti-HIV/química , Fármacos Anti-HIV/farmacologia , Anti-Infecciosos/química , Anti-Infecciosos/farmacologia , Linfócitos T CD4-Positivos , Carragenina/farmacologia , Celulose/análogos & derivados , Celulose/farmacologia , Defensinas/imunologia , Defensinas/farmacologia , Feminino , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , Células HeLa , Humanos , Imunidade Inata/imunologia , Naftalenossulfonatos/farmacologia , Polieletrólitos , Vagina/imunologiaRESUMO
INTRODUCTION: Monitoring antiretroviral (ARV) drug resistance is of growing importance in the management of persons infected with HIV, but few reports document how genotypic and phenotypic resistance testing (GPT) has been used among patients receiving routine outpatient care. METHODS: We studied data from participants in the HIV Outpatient Study seen at 10 HIV clinics in the United States during 1999 to 2006. We restricted analyses to patients whom we considered eligible for GPT (i.e., had a documented HIV viral load >1000 copies/mL). We used multivariable general modeling to evaluate temporal trends in use of GPT among eligible patients and to identify factors associated with being tested during 1999 to 2002 and 2003 to 2006. RESULTS: Of 5594 active patients, 3995 (71%) were considered eligible for GPT in at least one year during 1999 to 2006 (declining from 50.2% in 1999 to 31.2% in 2006). The fraction of eligible patients receiving GPT increased from 11.2% in 1999 to 31.0% in 2003 (P < 0.001 for trend) and then stabilized at approximately 30% through 2006. Among persons tested, the annual percentage receiving only genotype testing declined over time (90% to 56%), whereas the percentage receiving genotype and phenotype testing increased (5.4% to 39.1%). The annual use of GPT for ARV-naïve patients increased over time and after 2003 exceeded the corresponding rates for ARV-experienced patients. In multivariable analyses, low CD4 count and high HIV viral load were consistently associated with GPT. Compared with other ARV-experienced patients, those who were triple ARV-class experienced were consistently more likely to be tested, whereas ARV-naïve were less likely to be tested during 1999 to 2002 and more likely during 2003 to 2006. In addition, women and heterosexual men (vs. men who have sex with men) and black patients (vs. white) were less likely to be tested during 1999 to 2002, whereas older patients were less likely to be tested during 2003 to 2006. DISCUSSION: The annual frequency of GPT use has increased almost threefold since 1999. GPT use among ARV-naïve patients has increased coincident with dissemination of recommendations. Although earlier sex and racial/ethnic disparities in testing have waned, older patients were significantly less likely to be tested in recent years.
Assuntos
Fármacos Anti-HIV/antagonistas & inibidores , Infecções por HIV/tratamento farmacológico , HIV-1 , Adulto , Estudos de Coortes , Farmacorresistência Viral , Feminino , Genótipo , Infecções por HIV/virologia , Humanos , Estudos Longitudinais , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Fenótipo , RNA Viral/genética , Estados Unidos/epidemiologiaRESUMO
IDX899 is a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) with potent in vitro activity against wild-type and NNRTI-resistant strains of human immunodeficiency virus type 1 (HIV-1) and with a high genetic barrier to resistance. Single rising doses of 50 and 100 (given by use of a 50-mg capsule) and 200, 400, 800, and 1,200 mg (given by use of a 200-mg capsule) of IDX899 or matching placebo were administered sequentially to cohorts of healthy male subjects, followed by the administration of multiple doses of 800 mg once daily (QD) or 400 mg twice daily (BID) for 7 days. A single dose of 400 mg was also administered to a cohort of females. IDX899 was administered orally under fasted (50- to 400-mg doses) and then fed (> or = 200-mg doses) conditions. Exposure to IDX899 was dose proportional and comparable in males and females. With a different drug-to-excipient ratio, the 50-mg capsule led to a higher exposure but a shorter mean terminal half-life (t(1/2)) of 6.2 to 6.8 h. The 200-mg capsule resulted in a more sustained exposure with a longer mean t(1/2) of 7.9 to 14.6 h. Food enhanced absorption by approximately twofold, while it delayed the time to the maximum concentration. The mean concentration at 24 h following the administration of a single 200-mg dose under fed conditions exceeded the in vitro protein binding-adjusted 90% inhibitory concentration by fourfold. The levels of plasma exposure were similar between the single dosing and the repeat dosing with 800 mg QD and was approximately twofold higher with 400 mg BID. Mean steady-state trough levels were 0.9 microg/ml (range, 0.2 to 2.5 microg/ml) and 2.1 microg/ml (range, 0.5 to 4.5 microg/ml) for the 800-mg QD and 400-mg BID regimens, respectively. The level of excretion of unchanged drug in urine was negligible. IDX899 was well tolerated; and no serious adverse events, dose-dependent adverse events, or laboratory abnormalities were detected. These favorable safety and pharmacokinetic results support further clinical studies with patients with HIV-1 infection by the use of a QD regimen.
Assuntos
Fármacos Anti-HIV , Transcriptase Reversa do HIV/antagonistas & inibidores , HIV-1/efeitos dos fármacos , Indóis , Ácidos Fosfínicos , Inibidores da Transcriptase Reversa/administração & dosagem , Adolescente , Adulto , Idoso , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/antagonistas & inibidores , Fármacos Anti-HIV/química , Fármacos Anti-HIV/farmacocinética , Método Duplo-Cego , Esquema de Medicação , Feminino , Humanos , Indóis/administração & dosagem , Indóis/efeitos adversos , Indóis/química , Indóis/farmacocinética , Masculino , Pessoa de Meia-Idade , Ácidos Fosfínicos/administração & dosagem , Ácidos Fosfínicos/efeitos adversos , Ácidos Fosfínicos/química , Ácidos Fosfínicos/farmacocinética , Inibidores da Transcriptase Reversa/efeitos adversos , Inibidores da Transcriptase Reversa/química , Inibidores da Transcriptase Reversa/farmacocinética , Resultado do Tratamento , Adulto JovemRESUMO
Posttranslational proteolytic processing of chemokines is a natural mechanism to regulate inflammation. In this study, we describe modification of the CXC chemokine stromal cell-derived factor 1alpha/CXCL12 by peptidylarginine deiminase (PAD) that converts arginine residues into citrulline (Cit), thereby reducing the number of positive charges. The three NH(2)-terminal arginines of CXCL12, Arg(8), Arg(12), and Arg(20), were citrullinated upon incubation with PAD. The physiologic relevance of citrullination was demonstrated by showing coexpression of CXCL12 and PAD in Crohn's disease. Three CXCL12 isoforms were synthesized for biologic characterization: CXCL12-1Cit, CXCL12-3Cit, and CXCL12-5Cit, in which Arg(8), Arg(8)/Arg(12)/Arg(20), or all five arginines were citrullinated, respectively. Replacement of only Arg(8) caused already impaired (30-fold reduction) CXCR4 binding and signaling (calcium mobilization, phosphorylation of ERK and protein kinase B) properties. Interaction with CXCR4 was completely abolished for CXCL12-3Cit and CXCL12-5Cit. However, the CXCR7-binding capacities of CXCL12-1Cit and CXCL12-3Cit were, respectively, intact and reduced, whereas CXCL12-5Cit failed to bind CXCR7. In chemotaxis assays with lymphocytes and monocytes, CXCL12-3Cit and CXCL12-5Cit were completely devoid of activity, whereas CXCL12-1Cit, albeit at higher concentrations than CXCL12, induced migration. The antiviral potency of CXCL12-1Cit was reduced compared with CXCL12 and CXCL12-3Cit and CXCL12-5Cit (maximal dose 200 nM) could not inhibit infection of lymphocytic MT-4 cells with the HIV-1 strains NL4.3 and HE. In conclusion, modification of CXCL12 by one Cit severely impaired the CXCR4-mediated biologic effects of this chemokine and maximally citrullinated CXCL12 was inactive. Therefore, PAD is a potent physiologic down-regulator of CXCL12 function.
Assuntos
Fármacos Anti-HIV/antagonistas & inibidores , Quimiocina CXCL12/metabolismo , Citrulina/metabolismo , Mediadores da Inflamação/antagonistas & inibidores , Receptores CXCR4/antagonistas & inibidores , Receptores CXCR4/metabolismo , Receptores CXCR/antagonistas & inibidores , Receptores CXCR/metabolismo , Animais , Fármacos Anti-HIV/metabolismo , Fármacos Anti-HIV/farmacologia , Ligação Competitiva , Células CHO , Linhagem Celular Tumoral , Células Cultivadas , Quimiocina CXCL12/biossíntese , Quimiocina CXCL12/genética , Quimiocina CXCL12/fisiologia , Cricetinae , Cricetulus , Doença de Crohn/enzimologia , Doença de Crohn/imunologia , Doença de Crohn/metabolismo , Humanos , Hidrolases/biossíntese , Hidrolases/genética , Hidrolases/metabolismo , Mediadores da Inflamação/metabolismo , Mediadores da Inflamação/fisiologia , Ligação Proteica/imunologia , Desiminases de Arginina em Proteínas , Receptores CXCR/fisiologia , Receptores CXCR4/fisiologiaRESUMO
Azidothymidine (AZT) is known to decrease HIV virus replication and is one of the most frequently prescribed antiretroviral drugs used for AIDS treatment. Dose-limiting toxicities are the major curse associated with AZT therapy. Recently, we have reported that tannic acid; a PARG inhibitor prevents cisplatin induced nephrotoxicity. The present work was conceived to study the effect of tannic acid on AZT induced hepatotoxicity and genotoxicity. AZT induces increase in plasma levels of ALT, AST and alkaline phosphatase along with increase in micronucleus (MN) count in peripheral blood. Suggesting, AZT is hepatotoxic and genotoxic to mice. Treatment of tannic acid protects AZT induced hepatotoxicity by decreasing the ALT, AST and alkaline phosphatase levels. It also significantly reduces the oxidative damage by preventing reduction in glutathione and decreasing the level of malondialdehyde in liver of AZT treated mice. In addition, tannic acid decreases the PARG expression, PARP cleavage and histone H3 acetylation in liver of AZT treated mice. Moreover, treatment of tannic acid also decreases MN count in peripheral blood, suggesting its anti-mutagenic effect. In light of these findings we suggest the potential role of tannic acid treatment in preventing AZT induced toxicity.
Assuntos
Fármacos Anti-HIV/antagonistas & inibidores , Dano ao DNA/efeitos dos fármacos , Glicosídeo Hidrolases/metabolismo , Histonas/metabolismo , Hepatopatias/prevenção & controle , Taninos/farmacologia , Zidovudina/antagonistas & inibidores , Acetilação/efeitos dos fármacos , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Animais , Fármacos Anti-HIV/toxicidade , Aspartato Aminotransferases/sangue , Doença Hepática Induzida por Substâncias e Drogas , Fígado/efeitos dos fármacos , Fígado/metabolismo , Fígado/patologia , Hepatopatias/patologia , Malondialdeído/análise , Camundongos , Testes para Micronúcleos , Estresse Oxidativo/efeitos dos fármacos , Poli(ADP-Ribose) Polimerase-1 , Poli(ADP-Ribose) Polimerases/metabolismo , Taninos/uso terapêutico , Zidovudina/toxicidadeRESUMO
Stavudine (Zerit, d4T) is widely used as an anti HIV infection drug. It prevents HIV by altering the genetic material of healthy cells but causes mutations in mitochondrial and nuclear DNA. It also produces clastogenic effects in mice. In the present investigation, comet assay test was applied to evaluate the possible genomic damage caused by stavudine and also the ameliorating effects of garlic oil and vitamin E against its genotoxicity in different organs of mice. Two different doses of garlic oil (low and high dose) and vitamin E were administered to mice separately and in combination for six consecutive days followed by a dose of stavudine. The mice were sacrificed after 24, 48 and 72 h of stavudine administration. Both the antioxidants (vitamin E and garlic oil) separately and in combination reduced the genotoxicity of stavudine. The protective effects of high doses of garlic oil were more pronounced as compared to vitamin E administered group.
Assuntos
Compostos Alílicos/administração & dosagem , Mutagênicos/toxicidade , Estavudina/antagonistas & inibidores , Estavudina/toxicidade , Sulfetos/administração & dosagem , Vitamina E/administração & dosagem , Animais , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/antagonistas & inibidores , Fármacos Anti-HIV/toxicidade , Ensaio Cometa , Dano ao DNA , Masculino , Metilnitronitrosoguanidina/administração & dosagem , Metilnitronitrosoguanidina/toxicidade , Camundongos , Especificidade de Órgãos , Estavudina/administração & dosagemRESUMO
A major limitation in the use of AZT for AIDS treatment is the occurrence of side effects, such as leukopenia. The effects of antioxidant vitamins C and E on AZT-induced leukopenia were investigated in mice. Mice were divided into four groups: (1) controls; (2) AZT-treated; (3) treated with AZT plus vitamins C and E; and (4) pre-treated with vitamins and then treated with AZT plus vitamins. Our results demonstrate that AZT causes leukopenia in mice, which was abrogated by administration of vitamins C and E in the pre-treated group. These vitamins prevented the decrease in cellular content induced by AZT in bone marrow and diminished peroxide levels in myeloid precursors in bone marrow. AZT also caused an increase in plasma malondialdehyde and blood oxidized glutathione levels, which was prevented by the administration of antioxidant vitamins. In conclusion, oxidative stress is involved in AZT-induced leukopenia which may be prevented by antioxidant treatment.
Assuntos
Fármacos Anti-HIV/antagonistas & inibidores , Antioxidantes/uso terapêutico , Ácido Ascórbico/uso terapêutico , Leucopenia/prevenção & controle , Vitamina E/uso terapêutico , Zidovudina/antagonistas & inibidores , Animais , Fármacos Anti-HIV/toxicidade , Células da Medula Óssea/efeitos dos fármacos , Leucopenia/induzido quimicamente , Masculino , Camundongos , Camundongos Endogâmicos , Zidovudina/toxicidadeRESUMO
BACKGROUND: Evaluation of microbicides for prevention of HIV-1 infection in macaque models for vaginal infection has indicated that the concentrations of active compounds needed for protection by far exceed levels sufficient for complete inhibition of infection in vitro. These experiments were done in the absence of seminal plasma (SP), a vehicle for sexual transmission of the virus. To gain insight into the possible effect of SP on the performance of selected microbicides, their anti-HIV-1 activity in the presence, and absence of SP, was determined. METHODS: The inhibitory activity of compounds against the X4 virus, HIV-1 IIIB, and the R5 virus, HIV-1 BaL was determined using TZM-bl indicator cells and quantitated by measuring beta-galactosidase induced by infection. The virucidal properties of cellulose acetate 1,2-benzene-dicarboxylate (CAP), the only microbicide provided in water insoluble, micronized form, in the presence of SP was measured. RESULTS: The HIV-1 inhibitory activity of the polymeric microbicides, poly(naphthalene sulfonate), cellulose sulfate, carrageenan, CAP (in soluble form) and polystyrene sulfonate, respectively, was considerably (range approximately 4 to approximately 73-fold) diminished in the presence of SP (33.3%). Formulations of micronized CAP, providing an acidic buffering system even in the presence of an SP volume excess, effectively inactivated HIV-1 infectivity. CONCLUSION: The data presented here suggest that the in vivo efficacy of polymeric microbicides, acting as HIV-1 entry inhibitors, might become at least partly compromised by the inevitable presence of SP. These possible disadvantages could be overcome by combining the respective polymers with acidic pH buffering systems (built-in for formulations of micronized CAP) or with other anti-HIV-1 compounds, the activity of which is not affected by SP, e.g. reverse transcriptase and zinc finger inhibitors.
Assuntos
Fármacos Anti-HIV/antagonistas & inibidores , Fármacos Anti-HIV/farmacologia , HIV-1/efeitos dos fármacos , Sêmen , Administração Intravaginal , Anilidas/farmacologia , Fármacos Anti-HIV/administração & dosagem , Carragenina/farmacologia , Linhagem Celular , Celulose/análogos & derivados , Celulose/farmacologia , Relação Dose-Resposta a Droga , Furanos/farmacologia , HIV-1/fisiologia , Humanos , Naftalenossulfonatos/farmacologia , Poliestirenos/farmacologia , TioamidasRESUMO
APOBEC3G and APOBEC3F exhibit antiretroviral activity primarily as a consequence of their ability to deaminate cytidines in retroviral DNA. Here, we compare the properties of APOBEC3F and APOBEC3G from human, macaque, and African green monkey (AGM). While all APOBEC proteins tested exhibited anti-HIV-1 activity, human APOBEC3F was, surprisingly, 10- to 50-fold less potent than human APOBEC3G. However, similar discrepancies in antiviral potency were not found when pairs of proteins from macaque and AGM were compared. Intrinsic differences in the ability of each APOBEC protein to induce hypermutation, rather than differences in packaging efficiency, partially accounted for variable antiretroviral activity. Each of four primate lentivirus Vif proteins reduced human and AGM APOBEC3F expression and antiviral activity, but all were only partially effective and species-specific effects were relatively minor. Overall, highly efficient and species-specific neutralization of APOBEC3G, and less efficient neutralization of APOBEC3F, appears to be a general property of Vif proteins.
Assuntos
Fármacos Anti-HIV , Citidina Desaminase/fisiologia , Desaminase APOBEC-3G , Sequência de Aminoácidos , Animais , Fármacos Anti-HIV/antagonistas & inibidores , Chlorocebus aethiops , Citidina Desaminase/antagonistas & inibidores , Citosina Desaminase/antagonistas & inibidores , Citosina Desaminase/química , Citosina Desaminase/fisiologia , Regulação da Expressão Gênica , Produtos do Gene vif/fisiologia , HIV-1/efeitos dos fármacos , HIV-1/crescimento & desenvolvimento , Humanos , Macaca mulatta , Mutação , Nucleosídeo Desaminases/antagonistas & inibidores , Nucleosídeo Desaminases/química , Nucleosídeo Desaminases/fisiologia , RNA Viral/genética , Proteínas Repressoras/antagonistas & inibidores , Proteínas Repressoras/química , Proteínas Repressoras/fisiologia , Homologia de Sequência de Aminoácidos , Montagem de Vírus , Inativação de Vírus , Produtos do Gene vif do Vírus da Imunodeficiência HumanaRESUMO
Potential contributors to the high rate of virologic failure observed for tenofovir, abacavir, and lamivudine include a low genetic barrier to resistance for this regimen and antagonistic drug-drug interactions. To examine the second possibility, we tested combinations of abacavir, tenofovir, and lamivudine against wild-type and drug-resistant HIV-1 in vitro using peripheral blood mononuclear cells and MT-4 cells. Antagonistic interactions were not detected for any combination. If the systems examined accurately reflect the in vivo situation, antagonism does not substantially contribute to the poor efficacy of this triple combination.
Assuntos
Adenina/análogos & derivados , Fármacos Anti-HIV/farmacologia , Didesoxinucleosídeos/farmacologia , HIV-1/efeitos dos fármacos , Lamivudina/farmacologia , Organofosfonatos/farmacologia , Adenina/antagonistas & inibidores , Adenina/farmacologia , Fármacos Anti-HIV/antagonistas & inibidores , Linhagem Celular Transformada , Didesoxinucleosídeos/antagonistas & inibidores , Farmacorresistência Viral Múltipla/genética , Quimioterapia Combinada , HIV-1/genética , Humanos , Lamivudina/antagonistas & inibidores , Mutação , Organofosfonatos/antagonistas & inibidores , TenofovirAssuntos
Fármacos Anti-HIV/antagonistas & inibidores , Fármacos Anti-HIV/farmacologia , HIV-1/efeitos dos fármacos , Inibidores da Transcriptase Reversa/farmacologia , Uridina/farmacologia , Linfócitos T CD4-Positivos/virologia , Linhagem Celular , Células Cultivadas , Antagonismo de Drogas , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , HIV-1/fisiologia , Células HeLa , Humanos , Leucócitos Mononucleares/virologiaRESUMO
The aim of this study was to determine molecular mechanism(s) responsible for the reduced thymidine kinase activity (TK) observed earlier in an arabinosylcytosine (araC) resistant lymphoid cell line (H9-araC cells), which was obtained following continuous cultivation of H9 cells in the presence of 0.5 microM araC. Compared to H9 cells, in H9-araC cells TK1 and TK2 gene expressions were reduced to 17.7% and 2.5%, respectively, and the cellular AZT accumulation was diminished to 35.8%. These cells were also found cross-resistant to azidothymidine (>42-fold). There was no significant difference in the expression of MDR1, MRP4 or TK protein. The lack of correlation between the expressions of TK protein and TK1 and TK2 suggests that post-translational factors may also play a role in the reduced TK activity in H9-araC cells. These findings suggest that araC affects TK expression at the genetic level.
Assuntos
Fármacos Anti-HIV/antagonistas & inibidores , Citarabina/farmacologia , Resistência a Medicamentos , Timidina Quinase/metabolismo , Zidovudina/antagonistas & inibidores , Subfamília B de Transportador de Cassetes de Ligação de ATP/metabolismo , Fármacos Anti-HIV/metabolismo , Western Blotting , Linhagem Celular , Relação Dose-Resposta a Droga , Regulação para Baixo , Linfócitos T , Timidina Quinase/análise , Timidina Quinase/biossíntese , Timidina Quinase/genética , Zidovudina/metabolismoRESUMO
In vitro exposure of murine bone marrow cells to increasing concentrations of zidovudine (AZT, 0.1-50 microM) had a concentration dependent suppressive effect on the growth of granulocyte-monocyte colony forming unit (CFU-GM) derived colonies. In our previous published study, the mechanism of AZT-induced suppression of erythroid colony forming unit (CFU-E) derived colonies was linked to a decrease in erythropoitin receptor (Epo-R) gene expression. In this study, we have observed that AZT exposure also induced a concentration dependent suppressive effect (35-90%) on GM-CSF receptor type alpha (GM-CSFR alpha) gene expression. The suppression of GM-CSFR alpha mRNA expression was specific, since AZT caused a much lower decrease (15-22%) on the IL-3 receptor type alpha (IL-3R alpha) message level, and had an insignificant effect on glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and c-myc message levels. Erythropoietin (Epo) therapy has been used for reversal of AZT induced erythroid toxicity. Exposure to increasing concentrations (10-500 U/ml) of GM-CSF was unable to override the suppressive effect of AZT on CFU-GM derived colonies, however, treatment in combination with IL-3 (10-250 U/ml) ameliorated the suppressive effects of AZT on CFU-GM and on GM-CSFR alpha and IL-3R alpha gene expression. These findings suggest a mechanism via which AZT may suppress granulocyte-monocyte specific differentiation in murine bone marrow cells. These data also suggest that a combination of GM-CSF and IL-3 may be a superior therapeutic intervention for AZT-induced neutropenia.
Assuntos
Fármacos Anti-HIV/farmacologia , Células da Medula Óssea/metabolismo , Regulação da Expressão Gênica/efeitos dos fármacos , Fator Estimulador de Colônias de Granulócitos e Macrófagos/farmacologia , Receptores de Fator Estimulador de Colônias de Granulócitos/antagonistas & inibidores , Zidovudina/farmacologia , Animais , Fármacos Anti-HIV/antagonistas & inibidores , Fármacos Anti-HIV/toxicidade , Células da Medula Óssea/efeitos dos fármacos , Células Cultivadas , DNA Antissenso/farmacologia , Interleucina-3/farmacologia , Masculino , Camundongos , Neutropenia/induzido quimicamente , Neutropenia/prevenção & controle , RNA/farmacologia , Receptores de Fator Estimulador de Colônias de Granulócitos/biossíntese , Receptores de Fator Estimulador de Colônias de Granulócitos/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Zidovudina/antagonistas & inibidores , Zidovudina/toxicidadeRESUMO
A series of 4'-ethynyl (4'-E) nucleoside analogs were designed, synthesized, and identified as being active against a wide spectrum of human immunodeficiency viruses (HIV), including a variety of laboratory strains of HIV-1, HIV-2, and primary clinical HIV-1 isolates. Among such analogs examined, 4'-E-2'-deoxycytidine (4'-E-dC), 4'-E-2'-deoxyadenosine (4'-E-dA), 4'-E-2'-deoxyribofuranosyl-2,6-diaminopurine, and 4'-E-2'-deoxyguanosine were the most potent and blocked HIV-1 replication with 50% effective concentrations ranging from 0.0003 to 0.01 microM in vitro with favorable cellular toxicity profiles (selectivity indices ranging 458 to 2,600). These 4'-E analogs also suppressed replication of various drug-resistant HIV-1 clones, including HIV-1(M41L/T215Y), HIV-1(K65R), HIV-1(L74V), HIV-1(M41L/T69S-S-G/T215Y), and HIV-1(A62V/V75I/F77L/F116Y/Q151M). Moreover, these analogs inhibited the replication of multidrug-resistant clinical HIV-1 strains carrying a variety of drug resistance-related amino acid substitutions isolated from HIV-1-infected individuals for whom 10 or 11 different anti-HIV-1 agents had failed. The 4'-E analogs also blocked the replication of a non-nucleoside reverse transcriptase inhibitor-resistant clone, HIV-1(Y181C), and showed an HIV-1 inhibition profile similar to that of zidovudine in time-of-drug-addition assays. The antiviral activity of 4'-E-thymidine and 4'-E-dC was blocked by the addition of thymidine and 2'-deoxycytidine, respectively, while that of 4'-E-dA was not affected by 2'-deoxyadenosine, similar to the antiviral activity reversion feature of 2',3'-dideoxynucleosides, strongly suggesting that 4'-E analogs belong to the family of nucleoside reverse transcriptase inhibitors. Further development of 4'-E analogs as potential therapeutics for infection with multidrug-resistant HIV-1 is warranted.
Assuntos
Fármacos Anti-HIV/farmacologia , Desoxirribonucleosídeos/farmacologia , HIV-1/efeitos dos fármacos , Fármacos Anti-HIV/antagonistas & inibidores , Desoxirribonucleosídeos/antagonistas & inibidores , Interações Medicamentosas , Resistência a Múltiplos Medicamentos/fisiologia , Estabilidade de Medicamentos , Infecções por HIV/virologia , HIV-1/isolamento & purificação , HIV-2/efeitos dos fármacos , Humanos , Testes de Sensibilidade MicrobianaRESUMO
The novel virucidal protein cyanovirin-N (CV-N) binds with equally high affinity to soluble forms of either H9 cell-produced or recombinant glycosylated HIV-1 gp120 (sgp120) or gp160 (sgp160). Fluorescence polarization studies showed that CV-N is also capable of binding to the glycosylated ectodomain of the HIV-envelope protein gp41 (sgp41) (as well as SIV glycoprotein 32), albeit with considerably lower affinity than the sgp120/CV-N interaction. Pretreatment of CV-N with either sgp120 or sgp41 abrogated the neutralizing activity of CV-N against intact, infectious HIV-1 virions. Isothermal calorimetry and optical biosensor binding studies showed that CV-N bound to recombinant sgp120 with a K(d) value ranging from 2 to 45 nM and to sgp41 with a K(d) value of 606 nM; furthermore, they indicated an approximate 5:1 stoichiometry for CV-N binding to sgp120 and a 1:1 stoichiometry for CV-N binding to sgp41. Circular dichroism studies additionally illuminated the binding of CV-N with both sgp120 and sgp41, providing the first direct evidence that conformational changes are a consequence of CV-N interactions with both HIV-1 envelope glycoproteins.
Assuntos
Fármacos Anti-HIV/farmacologia , Proteínas de Bactérias , Proteínas de Transporte/farmacologia , Proteína gp120 do Envelope de HIV/metabolismo , Proteína gp41 do Envelope de HIV/metabolismo , HIV/efeitos dos fármacos , Fármacos Anti-HIV/antagonistas & inibidores , Ligação Competitiva , Técnicas Biossensoriais , Calorimetria , Proteínas de Transporte/antagonistas & inibidores , Dicroísmo Circular , Polarização de Fluorescência , Proteína gp120 do Envelope de HIV/farmacologia , Proteína gp41 do Envelope de HIV/farmacologia , Proteínas Recombinantes/metabolismo , Espectrometria de Fluorescência , Fatores de TempoAssuntos
Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Fármacos Anti-HIV/antagonistas & inibidores , Antituberculosos/farmacologia , Sistema Enzimático do Citocromo P-450/efeitos dos fármacos , Inibidores da Protease de HIV/antagonistas & inibidores , Rifamicinas/farmacologia , Tuberculose Pulmonar/tratamento farmacológico , Antituberculosos/administração & dosagem , Interações Medicamentosas , Humanos , Rifabutina/farmacologia , Rifampina/farmacologia , Rifamicinas/administração & dosagemRESUMO
The metabolism of O6-propyl-carbovir and N6-propyl-carbovir, two selective inhibitors of HIV replication, has been evaluated in CEM cells. Both compounds were phosphorylated in intact cells to carbovir-5'-triphosphate. The metabolism of these two agents was inhibited by deoxycoformycin and mycophenolic acid, but not erythro-9-(2-hydroxy-3-nonyl)adenine. No evidence of the 5'-triphosphate of either compound was detected in CEM cells.
Assuntos
Fármacos Anti-HIV/metabolismo , Linhagem Celular/metabolismo , Didesoxinucleosídeos/metabolismo , Alquilação , Fármacos Anti-HIV/antagonistas & inibidores , Fármacos Anti-HIV/síntese química , Didesoxinucleosídeos/antagonistas & inibidores , Didesoxinucleosídeos/síntese química , HIV-1/efeitos dos fármacos , HIV-1/metabolismo , Ácido Micofenólico/farmacologia , Pentostatina/farmacologia , Fosforilação/efeitos dos fármacos , Replicação Viral/efeitos dos fármacosRESUMO
The anti-HIV drug 3'-azido-3'-deoxythymidine (AZT) is used successfully for reduction of perinatal viral transmission. However toxic side effects including carcinogenesis are possible. To test this, pregnant CD-1 Swiss mice were given 25.0 or 12.5 mg AZT on gestation days 12-18. Previously we reported an increase in lung, liver, and female reproductive system tumors in offspring euthanized at 1 year (Olivero et al., J. Natl. Cancer Inst. 89, 1602-1608, 1997). Findings for all remaining offspring up to 2 years old are reported here. AZT effects were most prominent in female offspring, with a significant threefold increase in lung tumors, a reduction in lymphoblastic and follicle center cell lymphomas, and a significant increase in histiocytic sarcomas (0 in controls, 3% after low-dose AZT, and 8% after high-dose AZT, p = 0.022). Dose-dependent incidences of mammary gland, ovarian, and seminal vesicle tumors were low but significant: 0/106 controls, 3/105 low-dose, and 8/105 high-dose mice presented one of these neoplasms (p = 0.0025). Incidences of females showing any clearly AZT-related neoplasm, in lung, liver, ovary, or mammary gland or histiocytic sarcoma, in the second year, were 12/32 after the low dose and 14/27 after the high dose vs 3/23 controls (p = 0.0045). Also, the sensitivity of neonatal mice was assessed by administration of 25, 50, 100, or 200 mg/kg AZT on postnatal days 1 through 8. The effects at 2 years were similar to those seen after transplacental exposure, with significant increases in lung, liver, and mammary tumors in females. The results confirm that AZT is a moderately effective perinatal carcinogen in mice, targeting several tissue types.